Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Haemonetics (HAE) EBITDA (2016 - 2025)

Haemonetics has reported EBITDA over the past 17 years, most recently at $67.4 million for Q4 2025.

  • Quarterly results put EBITDA at $67.4 million for Q4 2025, up 307.05% from a year ago — trailing twelve months through Dec 2025 was $251.1 million (up 109.64% YoY), and the annual figure for FY2025 was $221.8 million, up 34.53%.
  • EBITDA for Q4 2025 was $67.4 million at Haemonetics, up from $58.5 million in the prior quarter.
  • Over the last five years, EBITDA for HAE hit a ceiling of $71.3 million in Q1 2025 and a floor of -$21.2 million in Q2 2021.
  • Median EBITDA over the past 5 years was $30.6 million (2024), compared with a mean of $30.9 million.
  • Biggest five-year swings in EBITDA: plummeted 181.42% in 2021 and later skyrocketed 427.28% in 2022.
  • Haemonetics' EBITDA stood at $14.4 million in 2021, then soared by 159.36% to $37.4 million in 2022, then grew by 5.79% to $39.6 million in 2023, then crashed by 58.15% to $16.6 million in 2024, then skyrocketed by 307.05% to $67.4 million in 2025.
  • The last three reported values for EBITDA were $67.4 million (Q4 2025), $58.5 million (Q3 2025), and $53.9 million (Q2 2025) per Business Quant data.